Trabectedin as second-line therapy for advanced translocation-related sarcoma

Trial Profile

Trabectedin as second-line therapy for advanced translocation-related sarcoma

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2015

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 According to a PharmaMar media release, data from this study will be presented at the 18th ECCO - 40th ESMO European Cancer Congress (ECC 2015).
    • 30 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top